Tongji School of Pharmacy, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, PR China.
Eur J Med Chem. 2012 Feb;48:305-12. doi: 10.1016/j.ejmech.2011.12.032. Epub 2011 Dec 28.
Two classes of dibutyltin(IV) hydroxamates complexes, formulated as the mononuclear mixed-ligand diorganotin(IV) complex [(n)Bu(2)Sn(HL)Cl] a and the tetranuclear (n)Bu(4)Sn(2)(HL)(2)(L)b were fully characterized. X-ray diffraction analyses were also carried out for the representative complexes (n)Bu(2)Sn(2,6-F(2)C(6)H(3)C(O)NHO)Cl and (n)Bu(4)Sn(2){3-BrC(6)H(4)C(O)NHO}(2){3-BrC(6)H(4)C(NO)O}. The cytotoxicity of all compounds was tested by MTT and SRB assays against three human tumor cell lines HL-60, BGC-823 and KB. 1b and 4a have been shown to be more potent antitumor agents than other compounds and cisplatin. Annexin V FITC-PI assay was consistent with the MTT results. Cell cycle assay results indicated that KB cells displayed an arrest in the G(0)/G(1) phase and a decrease of S phase of the cell cycle at the low concentrations of 1b, 4a.
两类二丁基锡(IV)羟胺配合物,被配方制成单核混合配体二有机锡(IV)配合物[(n)Bu(2)Sn(HL)Cl] a 和四核(n)Bu(4)Sn(2)(HL)(2)(L)b,它们都被充分地进行了特征描述。X 射线衍射分析也对具有代表性的配合物(n)Bu(2)Sn(2,6-F(2)C(6)H(3)C(O)NHO)Cl和(n)Bu(4)Sn(2){3-BrC(6)H(4)C(O)NHO}(2){3-BrC(6)H(4)C(NO)O}进行了研究。所有化合物的细胞毒性都通过 MTT 和 SRB 测定法在三种人类肿瘤细胞系 HL-60、BGC-823 和 KB 上进行了测试。1b 和 4a 被证明比其他化合物和顺铂具有更强的抗肿瘤活性。Annexin V FITC-PI 检测与 MTT 结果一致。细胞周期检测结果表明,在低浓度的 1b、4a 作用下,KB 细胞的细胞周期被阻滞在 G(0)/G(1)期,S 期减少。